14:03:46 Europe / Stockholm
Svenska | English
Investor Relations
Public Relations

Magle Chemoswed

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

2025-04-25 Årsstämma 2025
2025-02-26 Bokslutskommuniké 2024
2024-10-24 Kvartalsrapport 2024-Q3
2024-07-18 Kvartalsrapport 2024-Q2
2024-04-26 Ordinarie utdelning MAGLE 0.00 SEK
2024-04-25 Årsstämma 2024
2024-04-18 Kvartalsrapport 2024-Q1
2024-02-16 Bokslutskommuniké 2023
2023-10-25 Kvartalsrapport 2023-Q3
2023-07-18 Kvartalsrapport 2023-Q2
2023-04-27 Ordinarie utdelning MAGLE 0.00 SEK
2023-04-26 Årsstämma 2023
2023-02-16 Bokslutskommuniké 2022
2022-11-09 Kvartalsrapport 2022-Q3
2022-08-17 Kvartalsrapport 2022-Q2
2022-05-19 Ordinarie utdelning MAGLE 0.00 SEK
2022-05-17 Årsstämma 2022
2022-05-05 Kvartalsrapport 2022-Q1
2022-02-25 Bokslutskommuniké 2021
2021-12-14 Extra Bolagsstämma 2021
2021-11-16 Kvartalsrapport 2021-Q3
2021-08-17 Kvartalsrapport 2021-Q2
2021-05-14 Kvartalsrapport 2021-Q1
2021-05-03 Ordinarie utdelning MAGLE 0.00 SEK
2021-04-18 Årsstämma 2021
2021-02-25 Bokslutskommuniké 2020
2020-11-27 Extra Bolagsstämma 2020
2020-11-05 Kvartalsrapport 2020-Q3
2020-07-14 Kvartalsrapport 2020-Q2

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
Magle Chemoswed är verksamt inom läkemedelsbranschen. Bolaget är specialiserat inom utveckling av analytiska program. Produktportföljen är bred och inkluderar exempelvis program för intern uppföljning, process- samt systemhantering. Utöver huvudverksamheten erbjuds även service och tillhörande kringtjänster inom arbetsområdet. Verksamheten drivs globalt med störst närvaro inom den nordiska marknaden. Magle Chemoswed har sitt huvudkontor i Malmö.
Magle Chemsowed Holding AB (PUBL) – PUBLISHES FULL YEAR REPORT 2021
2022-02-25 08:29:00

Magle Chemoswed Holding AB (publ), an established innovation led healthcare group with proven growth through risk diversification and focus on high-value revenue streams, today publishes the interim report for the fourth quarter 2021 and the full year 2021.

SOLID REVENUES WITH INCREASED RETURNS
 
OCTOBER – DECEMBER 2021

  • Net sales amounted to 35.9 MSEK (35.6)
  • EBITDA equalled 4.4 MSEK (2.7)
  • Operating profit (EBIT) is 1.3 MSEK (0.1)
  • Profit after tax amounted to 1.1 MSEK (-0.1)
  • Earnings per share amounted to SEK 0.11 (-0.01) per share

 
JANUARY – DECEMBER 2021

  • Net sales amounted to 132.2 MSEK (142.3) adjusted for revenue recognition change in 2021 net sales amounted to 139.3 (142.3)
  • EBITDA equalled 16.9 MSEK (16.2)
  • Operating profit (EBIT) is 5.3 MSEK (4.5)
  • Profit after tax amounted to 4.4 MSEK (1.8)
  • Earnings per share amounted to SEK 0.4 (0.2) per share


Justin Pierce, CEO of Magle Chemoswed Holding AB, commented, “I am proud of our many contributions that we have made in 2021, we remain on track strategically and the focus on profitability and return for 2021 has met our expectations and demonstrates the underlying stability of the business.”

 
EVENTS DURING THE REPORTING PERIOD
 
Martin Lidgard appointed to the Board of Directors
 
EVENTS AFTER THE REPORTING PERIOD
 
Simon Jegou joined as new Chief Strategy Officer
Ethical approval granted for the post market clinical study for SmartPan®.

The full report can be downloaded at https://maglegroup.com/financial-reports/

Contacts

Justin Pierce, CEO, phone +46 (0)70 593 58 21, justin.pierce@maglechemoswed.com

About Us

Magle Chemoswed is a unique international contract development manufacturing company dedicated to bringing ideas to product for customers alongside building our own product pipeline based on our patented technology base. As an integrated company, we have extensive capabilities across the value chain, from the discovery, development and manufacture of medicines and medical devices that rely on our patented and trade secret protected technology platform. Learn more on www.maglechemoswed.com and https://maglegroup.com/

Västra Hamnen Corporate Finance is the Company's certified advisor on Nasdaq First North Growth Market and can be reached at ca@vhcorp.se or +46 (0) 40 200 250.

This information is information that Magle Chemoswed is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2022-02-25 08:29 CET.

Attachments

MagleChemoswed 2021 Full Year

Källa MFN
Enter your email address and you will get a mail for verification you subscription to content on this page and filter


Select the time zone location for site wide time

Europe
London
Oslo
Stockholm
Helsinki

America
New York / Eastern
Chicago / Central
Los Angeles / Western

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden